Title:
免疫抑制のためのＦＬＴ３阻害剤
Document Type and Number:
Japanese Patent JP5704785
Kind Code:
B2
Abstract:
New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.
Inventors:
Small donald
Wartenby A Catherine
Paddle drew
Wartenby A Catherine
Paddle drew
Application Number:
JP2007522605A
Publication Date:
April 22, 2015
Filing Date:
July 14, 2005
Export Citation:
Assignee:
The Johns Hopkins University
International Classes:
A61K31/498; A61K31/553; A61P3/10; A61P7/04; A61P7/06; A61P17/00; A61P17/06; A61P19/02; A61P21/04; A61P25/00; A61P25/28; A61P29/00; A61P37/06; A61P43/00
Domestic Patent References:
| JP2004519475A | ||||
| JP2004513126A |
Foreign References:
| WO2004058749A1 | ||||
| WO2003037347A1 |
Other References:
GRISWOLD,I.J. et al,Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis,Blood,2004年,Vol.104, No.9,p.2912-8,Epub 2004 Jul 8
Gilliland DG., et al.,Therapeutic efficacy of all-trans-retinoic acid (ATRA) combined with the FLT3 inhibitor MLN518 in a murine model of acute promyelocytic leukemia,Blood American Society of Hematology,2003年,Vol.102、No.11,66a,#222
LEVIS,M. et al,A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo,Blood,2002年,Vol.99, No.11,p.3885-91
Gilliland DG., et al.,Therapeutic efficacy of all-trans-retinoic acid (ATRA) combined with the FLT3 inhibitor MLN518 in a murine model of acute promyelocytic leukemia,Blood American Society of Hematology,2003年,Vol.102、No.11,66a,#222
LEVIS,M. et al,A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo,Blood,2002年,Vol.99, No.11,p.3885-91
Attorney, Agent or Firm:
Norio Saeki
Yuko Saeki
Naoko Ushiyama
Yuko Saeki
Naoko Ushiyama